Example of graft-versus-tumor response. Patient no. 20, as shown in Table 1, was a 69-year-old man with rapidly progressive mantle cell NHL. Prior treatments included 8 lines of chemotherapy with only a 6-month remission to high-dose radiolabeled antibodies with autologous peripheral blood stem cell support. At the time of transplantation, he had kinetically failed Etoposide, Methylprednisolone, Ara-C Cisplatin (ESHAP), with rapidly progressive disease during the pretransplantation workup. (A) Pretransplantation computed tomography (CT) scan image (day –27) through the upper pelvis demonstrating an 8-cm by 7-cm mass that extended through twelve 0.5-cm cuts. (B) CT scan image through the same region demonstrating complete resolution of the mass on day +74 after nonmyeloablative transplantation from a matched unrelated donor. The patient remains in remission 30 months after transplantation with no evidence of GVHD.